乳腺癌女性接受或不接受激素治疗时子宫内膜改变的超宫腔镜评估:一项大型多中心队列研究结果
该多中心回顾性队列研究纳入2007年1月至2016年12月因超声或临床指征行宫腔镜检查的乳腺癌患者,比较他莫昔芬(TAM)、芳香化酶抑制剂(AIs)或无治疗(NT)三组子宫内膜病理发生率。TAM组和AI组子宫内膜正常者比例高于NT组,NT组子宫内膜息肉发生率高于其他两组;三组间其他良性病变及癌前和恶性子宫疾病(如子宫内膜不典型增生和腺癌)无显著差异。结论认为,与AIs或NT相比,TAM治疗似乎并不增加乳腺癌女性子宫内膜癌的发生率。
要点
- TAM组和AI组子宫内膜正常者比例高于NT组,NT组子宫内膜息肉发生率高于其他两组。
- 三组间其他良性病变及子宫内膜不典型增生和腺癌等癌前和恶性病变无显著差异。
- TAM治疗似乎不增加乳腺癌女性子宫内膜癌发生率。
核心结论
- 与AIs或NT相比,TAM治疗似乎并不增加乳腺癌女性子宫内膜癌的发生率。
研究设计与样本
- 多中心回顾性队列研究(临床试验ID:NCT03898947),数据来自意大利罗马Regina Elena国家癌症研究所、罗马Arbor Vitae中心、墨西拿Gaetano Martino大学医院和巴勒莫Villa Sofia-Cervello医院。
- 连续纳入2007年1月至2016年12月期间因超声或临床指征行宫腔镜检查且有乳腺癌病史的患者。
- 干预为诊断性宫腔镜加子宫内膜活检,临床需要时行宫腔镜手术。
主要发现
- TAM组和AI组子宫内膜正常者比例高于NT组。
- NT组子宫内膜息肉发生率高于TAM组和AI组。
- 三组间其他良性病变及子宫内膜不典型增生和腺癌等癌前和恶性子宫疾病无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: The primary aim of our study was to investigate the incidence of endometrial pathologies, especially endometrial cancer, in women with breast cancer treated with tamoxifen (TAM), aromatase inhibitors (AIs), or receiving no treatment (NT). The secondary aim was to identify, in this cohort, ultrasonographic findings that represent robust indications for hysteroscopy and endometrial biopsy, to avoid unnecessary second-level diagnostic procedures. DESIGN: Multicenter retrospective cohort study (Clinical Trial ID: NCT03898947). SETTING: Data were collected from different Italian centers: Regina Elena National Cancer Institute of Rome, Arbor Vitae Centre of Rome, Gaetano Martino University Hospital of Messina, and Villa Sofia-Cervello Hospital of Palermo. PATIENTS: We selected and consecutively included patients with a history of breast cancer who had undergone hysteroscopy for ultrasonographic or clinical indications between January 2007 and December 2016. INTERVENTIONS: Diagnostic hysteroscopy with endometrial biopsy or operative hysteroscopy, when clinically indicated. MEASUREMENTS AND MAIN RESULTS: A higher percentage of patients in the TAM and AI groups had a normal endometrium compared with those in the NT group, whereas the incidence of endometrial polyps was higher in the NT group than in the others; no significant differences were observed among the 3 groups for other benign conditions or for premalignant and malignant uterine diseases, such as endometrial atypical hyperplasia and adenocarcinoma. CONCLUSION: TAM treatment does not seem to be associated with a higher rate of endometrial cancer in women with breast cancer compared with women treated with AIs or NT.
引用
- Chiofalo B, Mazzon I, Di Angelo Antonio S, et al. Hysteroscopic Evaluation of Endometrial Changes in Breast Cancer Women with or without Hormone Therapies: Results from a Large Multicenter Cohort Study. J Minim Invasive Gynecol. 2019. PMID: 31425735. doi:10.1016/j.jmig.2019.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。